Tokyo, Japan

Masashi Aoki

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Tokyo, JP (1991 - 2010)
  • Chiyoda-ku, JP (2020 - 2021)

Company Filing History:


Years Active: 1991-2021

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Masashi Aoki: Innovator in Thiazole Derivative Production

Introduction

Masashi Aoki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the production of thiazole derivatives. With a total of 6 patents to his name, Aoki's work has the potential to impact various therapeutic areas.

Latest Patents

Aoki's latest patents focus on a production method of thiazole derivatives, which are represented by a specific formula. These compounds exhibit adenosine A receptor antagonistic action, making them useful as therapeutic agents for conditions such as Parkinson's disease, sleep disorders, analgesic resistance to opioids, migraines, movement disorders, depression, and anxiety disorders. The production method involves a reaction between compounds represented by specific formulas, showcasing Aoki's innovative approach to drug development.

Career Highlights

Throughout his career, Masashi Aoki has worked with notable companies, including Disco Corporation and Kyowa Kirin Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in pharmaceutical research.

Collaborations

Aoki has collaborated with talented individuals in his field, including Yusuke Nagai and Takamasa Sugita. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Masashi Aoki's contributions to the field of medicinal chemistry, particularly through his patents on thiazole derivatives, highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic agents that address critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…